Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Antivir Ther. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
Antivir Ther. 2010; 15(4): 571–577.
doi: 10.3851/IMP1557

Table 3

Factors Associated with Hemoglobin A1c Values in HIV-Infected Diabetic Women from Bivariate and Multivariate Linear Regression of Log Hemoglobin A1c

VariableBivariate modelaMultivariate modelb

Percent Changec95% Confidence IntervalP- valuePercent Changec95% Confidence IntervalP- value

Age (per 10 years)0.08-0.67, 0.830.8400.720.05, 1.380.034

 White-2.64-4.14, -1.12< 0.001-1.79-3.28, -0.280.020
 Other-2.24-3.75, -0.710.004-1.42-2.61, -0.220.021

Family history of diabetes mellitus0.55-0.75, 1.870.15

Diabetic medication5.654.21, 7.10< 0.0014.913.50, 6.34< 0.001

cART use-1.41-2.60, -0.200.023

PI use-0.38-1.61, 0.870.548

NNRTI use-1.80-3.04, -0.550.005

Zidovudine use-1.59-2.99, -0.170.029

Stavudine use-0.96-2.17, 0.260.123

Abacavir use-0.84-2.25, 0.590.247

BMI category (kg/m2)
< 25referent
≥ 25 – 29-0.83-2.42, 0.790.313
≥ 301.44-0.15, 3.050.075

Hemoglobin (g/dL)-0.41-0.79, -0.020.038

Mean corpuscular volume (per 10 fL)-1.86-2.36, -1.36< 0.001-1.77-2.21, -1.33< 0.001

Albumin (g/dL)-1.18-2.38, 0.030.056

CD4 (per 100 cells/mm3)0.13-0.06, 0.320.1810.230.05, 0.400.011

Detectable HIV RNA-1.06-2.27, 0.130.080

HCV RNA positive-1.12-2.49, 0.270.114-1.44-2.69, -0.180.025
aAdjusted for log plasma glucose concentration
bFinal model from stepwise multiple regression model of all variables in this table (including log glucose, which was forced into the model)
cReflects the percentage change on a multiplicative scale relative to the referent group, obtained as 100(expβ-1) where β is the regression coefficient (or corresponding lower or upper confidence limit for this coefficient) using log-transformed hemoglobin A1c as the outcome

Abbreviations: cART, combination antiretroviral; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor